Response Comparison of Disease Modifying Anti-rheumatic Drugs for Ankylosing Spondylitis: Systematic Review of Network Meta-analyses
Main Article Content
Abstract
Introduction: Ankylosing spondylitis (AS) presents challenges in selecting first-line biologic disease-modifying anti-rheumatic drugs (b-DMARDs) due to uncertainty about their effectiveness. Additionally, new research has introduced targeted synthetic DMARDs (ts-DMARDs) as treatment options. This systematic review compares the effectiveness of various DMARDs, both biologic and targeted, for AS patients. Materials and methods: A literature search was performed in several databases with the keywords “ankylosing spondylitis”, “DMARDs”, “efficacy”, and “network meta-analysis” with its synonym applied. Inclusion criteria were network meta-analysis (NMAs), ≥18-year-old patients with AS, and language in Bahasa or English. Critical appraisal of selected NMAs was carried out according to the ISPOR guideline for NMA. This study is registered in PROSPERO with the ID of CRD42024563670. Results: Eleven NMAs based on randomized clinical trials were included. Infliximab was found to have the greatest probability of eliciting a response across various assessments (ASAS 20, ASAS 40, BASDAI 50, and BASFI). Among subcutaneous biologics, Golimumab demonstrated the highest probability of response. The evidence for ts-DMARDs, such as JAK inhibitors, indicates they may be viable alternatives if established treatments do not achieve remission. However, these results should be interpreted with caution due to statistical insignificance in several NMAs, likely from limited direct comparisons between DMARDs. Conclusion: Infliximab appears to have a higher likelihood of achieving responses in various assessments, and Golimumab may be considered for those preferring subcutaneous administration. Both treatments may be promising options for first-line therapy, but these conclusions should be viewed cautiously until future RCTs provide more robust comparative data on DMARDs.
Downloads
Article Details
References
Migliore A, Gigliucci G, Integlia D, Isailovic N, Frediani B. Differences in biologics for treating ankylosing spondylitis: the contribution of network meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(1):56–64. doi: 10.26355/eurrev_202101_24347.
Cao Z, Guo J, Li Q, Li Y, Wu J. Optimal Biologic Drugs for the Treatment of Ankylosing Spondylitis: Results from a Network Meta-Analysis and Network Metaregression. Biomed Res Int. 2022;2022:1–13. doi: 10.1155/2022/8316106.
Deodhar A, Chakravarty SD, Cameron C, Peterson S, Hensman R, Fogarty S, et al. A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis. Clin Rheumatol. 2020;39(8):2307–15. doi: 10.1007/s10067-020-04970-3.
Chen C, Zhang X, Xiao L, Zhang X, Ma X. Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis. Medicine. 2016;95(11):e3060. doi: 10.1097/MD.0000000000003060.
Liu W, Wu Y, Zhang L, Liu X, Bin Xue, Bin Liu, et al. Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis. Sci Rep. 2016;6(1):32768. doi: 10.1038/srep32768.
Migliore A, Bizzi E, Bernardi M, Picchianti Diamanti A, Laganà B, Petrella L. Indirect Comparison Between Subcutaneous Biologic Agents in Ankylosing Spondylitis. Clin Drug Investig. 2015;35(1):23–9. doi: 10.1007/s40261-014-0246-6.
Machado MADÁ, Barbosa MM, Almeida AM, De Araújo VE, Kakehasi AM, Andrade EIG, et al. Treatment of ankylosing spondylitis with TNF blockers: A meta-analysis. Rheumatol Int. 2013;33(8):2199–213. doi: 10.1007/s00296-013-2772-6.
Betts KA, Griffith J, Song Y, Mittal M, Joshi A, Wu EQ, et al. Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis. Rheumatol Ther. 2016;3(2):323–36. doi: 10.1007/s40744-016-0038-y.
Mei L, Gao K, He X, Jakobsson P-J, Huang R. Editorial: Disease-modifying antirheumatic drugs: Approaches and lessons learned from traditional medicine. Front Pharmacol. 2023;14. doi: 10.3389/fphar.2023.1135803.
Migliore A, Broccoli S, Bizzi E, Laganà B. Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials. J Med Econ. 2012;15(3):473–80. doi: 10.3111/13696998.2012.660255.
Shu T, Chen GH, Rong L, Feng F, Yang B, Chen R, et al. Indirect comparison of anti-TNF-α agents for active ankylosing spondylitis: mixed treatment comparison of randomized controlled trials. Clin Exp Rheumatol. 2013;31(5):717–22.
Baji P, Péntek M, Szántó S, Géher P, Gulácsi L, Balogh O, et al. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. Eur J Health Econ. 2014;15(S1):45–52. doi: 10.1007/s10198-014-0593-5.
Wang R, Dasgupta A, Ward MM. Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis. J Rheumatol. 2018;45(4):481–90. doi: 10.3899/jrheum.170224.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552–63. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W.
Pharmacoeconomic Review Report: Upadacitinib (Rinvoq): (AbbVie): Indication: For the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2020.
Deodhar A, Braun J, Inman RD, van der Heijde D, Zhou Y, Xu S, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis. 2015;74(4):757–61. doi: 10.1136/annrheumdis-2014-205862.
Hebeisen M, Scherer A, Micheroli R, Nissen MJ, Tamborrini G, Möller B, et al. Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis. PLoS One. 2019;14(5):e0216746. doi: 10.1371/journal.pone.0216746.
Strand V, Burmester GR, Zerbini CAF, Mebus CA, Zwillich SH, Gruben D, et al. Tofacitinib With Methotrexate in Third‐Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial. Arthritis Care Res (Hoboken). 2015;67(4):475–83. doi: 10.1002/acr.22453.
Zhang H, Jiang H-L, Dai S-M. No Significant Effects of IL-23 on Initiating and Perpetuating the Axial Spondyloarthritis: The Reasons for the Failure of IL-23 Inhibitors. Front Immunol. 2022;13. doi: 10.3389/fimmu.2022.818413.
McGonagle D, Watad A, Sharif K, Bridgewood C. Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis. Front Immunol. 2021;12. doi: 10.3389/fimmu.2021.614255.
Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73(1):95–100. doi: 10.1136/annrheumdis-2013-203559.
Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015;74(6):1051–7. doi: 10.1136/annrheumdis-2013-204963.
Luque M, Zhelyazkova K, Vashishta L, Rai M, Sattar A, Bucknall R, et al. Assessment of Comparative Efficacy Between Candidate Biosimilar AVT05 and Reference Golimumab. Arthritis Rheumatol. 2024;76(Suppl 9).
Golimumab (Simponi) (Subcutaneous Injection): Adult Patients with Moderately to Severely Active Ulcerative Colitis Who Have Had an Inadequate Response to, or Have Medical Contraindications for, Conventional Therapies. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2014.